Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MabThera – Conclusions<br />
Sustained or improved efficacy with repeat treatment<br />
• Benefits of rituximab are sustained with repeated courses<br />
• Stopping joint damage progression remains a priority in inadequate responders to TNF<br />
inhibitors<br />
• REFLEX study provides first and only evidence of inhibition of structural joint damage in<br />
this patient population<br />
• This is independent of achieving a clinical response with rituximab<br />
Overall safety profile consistent with prior studies<br />
• Similar serious infection rates with repeat treatment courses – No opportunistic infections,<br />
viral reactivations or tuberculosis reported<br />
• No lymphoproliferative malignancies and no increased risk of malignancy with additional<br />
courses of treatment were observed<br />
• Long-term follow-up of RA patients receiving rituximab showed safety profile similar with<br />
each course<br />
53